X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration between Alloy and Normunity is leveraging Alloy’s high velocity antibody discovery services offering, Daedamab, which takes a sequencing-first approach to antibody discovery that reduces discovery timelines without sacrificing quality.
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alloy Therapeutics
Deal Size: $65.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 17, 2022
Details:
Proceeds from the financing will also be used to build on multiple discovery platforms in the Lieping Chen lab to pursue additional mechanisms that block normal anti-cancer immunity.
Lead Product(s): Monoclonal Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Canaan Ventures
Deal Size: $65.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
